RIGO, Riccardo, Elisabetta GROAZ a Claudia SISSI. Polymorphic and Higher-Order G-Quadruplexes as Possible Transcription Regulators: Novel Perspectives for Future Anticancer Therapeutic Applications. PHARMACEUTICALS. BASEL, SWITZERLAND: MDPI, 2022, roč. 15, č. 3, s. 373-385. ISSN 1424-8247. Dostupné z: https://dx.doi.org/10.3390/ph15030373.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Polymorphic and Higher-Order G-Quadruplexes as Possible Transcription Regulators: Novel Perspectives for Future Anticancer Therapeutic Applications
Autoři RIGO, Riccardo (380 Itálie, garant, domácí), Elisabetta GROAZ a Claudia SISSI.
Vydání PHARMACEUTICALS, BASEL, SWITZERLAND, MDPI, 2022, 1424-8247.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30104 Pharmacology and pharmacy
Stát vydavatele Švýcarsko
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.600
Kód RIV RIV/00216224:14740/22:00127513
Organizační jednotka Středoevropský technologický institut
Doi http://dx.doi.org/10.3390/ph15030373
UT WoS 000774500300001
Klíčová slova anglicky G-quadruplex; folding landscapes; gene promoters
Štítky rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Pavla Foltynová, Ph.D., učo 106624. Změněno: 3. 4. 2023 10:12.
Anotace
In the past two decades, significant efforts have been put into designing small molecules to target selected genomic sites where DNA conformational rearrangements control gene expression. G-rich sequences at oncogene promoters are considered good points of intervention since, under specific environmental conditions, they can fold into non-canonical tetrahelical structures known as G-quadruplexes. However, emerging evidence points to a frequent lack of correlation between small molecule targeting of G-quadruplexes at gene promoters and the expression of the associated protein, which hampers pharmaceutical applications. The wide genomic localization of G-quadruplexes along with their highly polymorphic behavior may account for this scenario, suggesting the need for more focused drug design strategies. Here, we will summarize the G4 structural features that can be considered to fulfill this goal. In particular, by comparing a telomeric sequence with the well-characterized G-rich domain of the KIT promoter, we will address how multiple secondary structures might cooperate to control genome architecture at a higher level. If this holds true, the link between drug–DNA complex formation and the associated cellular effects will need to be revisited.
Návaznosti
EF20_079/0017045, projekt VaVNázev: MSCAfellow4@MUNI
VytisknoutZobrazeno: 12. 10. 2024 21:45